Roche Holding AG has offered $43.7 billion, or $89 per share, to buy the 44 percent it does not own already of Genentech Inc., the world's largest biotech. (BioWorld Today)
WASHINGTON - The National Institute of Allergy and Infectious Diseases (NIAID) has scrapped a large-scale HIV vaccine study, known as PAVE 100, and has opted instead to conduct a smaller, more focused trial of the agency's investigational vaccine. (BioWorld Today)
The second fastest way to clear a room of venture capitalists and other investors is to announce a bomb threat or yell "fire." But the quickest way is to tell them you are a drug developer targeting traumatic brain injury (TBI) or stroke, said Harry Tracy, who runs Cardiff, Calif.-based NI Re-search, a consulting and research firm focused on the neurological and psychiatric therapeutics industry. (BioWorld Financial Watch)
Antibiotic maker ViroPharma Inc. is acquiring Lev Pharmaceuticals Inc. for $442.9 million up front, or $2.75 per share. The deal has a potential net aggregate value of up to $617.5 million if certain milestones are met. (BioWorld Today)
